Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cardiodoron is an anthroposophic medicinal product developed by Weleda AG, specifically formulated for the treatment of functional cardiovascular disorders, hypotension, and orthostatic circulatory regulation disturbances. The medication is a combination of three plant-derived extracts: *Onopordum acanthium* (Cotton thistle), *Hyoscyamus niger* (Henbane), and *Primula veris* (Cowslip). In anthroposophic medicine, Cardiodoron is intended to stabilize and harmonize the rhythmic relationship between the cardiovascular and respiratory systems. It is commonly used to manage symptoms such as dizziness, fatigue, and circulatory weakness, particularly in patients with constitutional low blood pressure or during recovery from illness. The *Hyoscyamus niger* component provides a pharmacological basis for its action through tropane alkaloids that act as muscarinic receptor antagonists, while the other components contribute to its overall regulatory effect on the autonomic nervous system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cardiodoron.